Condition
Gliomas Harboring IDH1 and/or IDH2 Mutations clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Gliomas Harboring IDH1 and/or IDH2 Mutations clinical trials that are recruiting, in China. By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Midline glioma MRI AI model: preoperative molecular subtyping and prognosis
This study tests an MRI-based AI model to predict key molecular subtypes and prognosis for patients with midline gliomas before surgery.
-
HMPL-306 treatment for gliomas with IDH1 or IDH2 mutations.
This study will test whether HMPL-306, a drug that blocks mutant IDH1 and IDH2, is safe and shows early benefit in adults with IDH‑mutant gliomas.
Related topics
Quick answers
How many Gliomas Harboring IDH1 and/or IDH2 Mutations clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.